Transcriptomic data indicated that elevated SLC7A5 expression enhances the suppression of ferroptosis, particularly post-immunotherapy, with TP63+ SLC7A5+ HNSCC subpopulation demonstrating significant inhibition of the ferroptosis phenotype. Here, SLC7A5 is linked to head and neck squamous cell carcinoma.